A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

This study is testing a new drug called ARV-393 in people with relapsed or treatment-resistant non-Hodgkin lymphoma (NHL) — a group of blood cancers that start in white blood cells called lymphocytes — who have run out of standard treatment options. **You may be eligible if...** - You have non-Hodgkin lymphoma that has returned or is no longer responding to treatment - You have received at least 2 prior treatments (including rituximab) - You have at least one measurable tumor on imaging - You are in good health (ECOG performance status 0 or 1; score 2 allowed in some groups with brain involvement) - Your bone marrow, kidney, and liver function are adequate **You may NOT be eligible if...** - You have a history of elevated eosinophils (a type of white blood cell) causing organ problems - You have had a prior allogeneic (donor) stem cell transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.